Wound Mgmt Tech (WNDM) 0.0570 $WNDM
Q2 2016 Sales Up 69% over Q2 2015, and 2016 YTD Sales Up 34% over 2015 YTD Sales for Wound Management Technologies
ACCESSWIRE - Fri Aug 12, 8:30AM CDT
ADDISON, TX / ACCESSWIRE / August 12, 2016 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX®, today announced its continued sales growth.
Wound Management Technologies Reports Positive Net Income for Q1 Ended March 31, 2016
ACCESSWIRE - Mon May 16, 8:30AM CDT
ADDISON, TX / ACCESSWIRE / May 16, 2016 / Wound Management Technologies, Inc. (OTC QB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX®, today announced that its sales growth and cost reducing measures have resulted in positive net income for the quarter This achieves a major corporate strategic milestone.
Wound Management Technologies Reports Record Preliminary Financial Results For Q1 Ended March 31, 2016
ACCESSWIRE - Tue Apr 19, 7:31AM CDT
ADDISON, TX / ACCESSWIRE / April 19, 2016 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX®, today announced record preliminary financial and operating results for Q1 ended March 31, 2016.
Wound Management Technologies Reports Preliminary Financial Results For Year Ended December 31, 2015
ACCESSWIRE - Thu Apr 07, 7:30AM CDT
ADDISON, TX / ACCESSWIRE / April 7, 2016 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX®, today announced preliminary financial and operating results for year ended December 31, 2015.
Markets for Advanced Wound Management Technologies
M2 - Mon Jan 04, 3:08AM CST
REPORT HIGHLIGHTS
Global Medical Devices: Quarterly Investments Review Featuring the Most Recent 200 Business Transactions
M2 - Tue Oct 20, 6:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mqnnl4/global_medical) has announced the addition of the "Global Medical Devices: Quarterly Investments Review " report to their offering. The 'Global Medical Devices: Quarterly Investments Review report' presents the most recent 200 business transactions between the global medical devices/technology/supplies companies are identified, segregated and analyzed to highlight the scope of investments in different sub-industry sectors. Medical device companies are expected to realign their business structures and strategies to compete in the changing global environment (such as growth of emerging markets, health care reform and cost containment). Anticipated changes include company restructuring as well as an increased reliance on strategic alliances and outsourcing for marketing, distribution, research and manufacturing activities. In this context, the author which has been providing company and financial information globally since two decades, brings out Global Medical Devices: Quarterly Investments Review report for global medical devices/technology/supplies companies. Report Highlights: - A guidance business tool which helps the investors in the global medical devices/technology/supplies industry to assess the investment opportunities for the coming months - Helps the investors to familiarize with the existing investment trends in the global medical devices/technology/supplies industry - Helps the global medical devices/technology/supplies companies to know the prevailing sub-industry trends in the global medical devices/technology/supplies business transactions - Presents the key investment strategies applied by the global medical devices/technology/supplies companies - Highlights the favored countries for the deals by the global medical devices/technology/supplies companies - Useful information on trade facilitators' activities to accelerate global medical devices/technology/supplies commerce - Summarizes the recent regulatory developments that are likely to affect the trade approaches of the global medical devices/technology/supplies industry - Summarizes new policies of various governments in global medical devices/technology/supplies industry and its impact on investments globally - Provides at one glance the listing of important transactions across the global medical devices/ technology/supplies sector Companies Mentioned - Simavita Ltd (Australia) - Solborn Incorporated (South Korea) - Sorin SpA (Italy) - Strand Life Sciences Private Limited (India) - Stratec Biomedical AG (Germany) - Straumann Holding AG (Switzerland) - Sunshine Holdings PLC (Sri Lanka) - Sysmex Corporation (Japan) - Thermo Fisher Scientific Inc (United States) - Tornier NV (Netherlands) - Toumaz Limited (United Kingdom) - TSO3 Inc (Canada) - Varian Medical Systems, Inc. (United States) - Vivoline Medical AB (Sweden) - Voxel SA (Poland) - William Demant Holding (Denmark) - Wound Management Technologies, Inc. (United States) - Yamato Scientific Co, Ltd (Japan) - Zecotek Photonics Inc (Canada) - Zhejiang DA Diagnostics Co Ltd (China) For more information visit http://www.researchandmarkets.com/research/mq...al_medical
VAR: 94.92 (-0.22), TRNX: 20.67 (+0.28)
Wound Management Technologies Reports Preliminary Financial Results for the Third Quarter of 2015
ACCESSWIRE - Wed Oct 07, 3:10PM CDT
ADDISON, TX / ACCESSWIRE / October 7, 2015 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced preliminary financial and operating results for the third quarter and nine months ended September 30, 2015.
Wound Management Technologies Elects Mr. James W. Stuckert to the Board of Directors
ACCESSWIRE - Thu Sep 24, 2:58PM CDT
ADDISON, TX / ACCESSWIRE / September 24, 2015 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that Mr. James W. Stuckert was elected to the Board of Directors of the Company at its September 21, 2015 board meeting.
Wound Management Technologies Receives Investment; Fully Pays Notes to Brookhaven Medical, Inc.; Mr. S. Oden Howell, Jr. Appointed to the Board of Directors
ACCESSWIRE - Thu Jun 18, 7:30AM CDT
ADDISON, TX / ACCESSWIRE / June 18, 2015 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that it has fully paid short term loans due to Brookhaven Medical Inc. This was made possible by investments from existing shareholders.
Wound Management Technologies Reports Amending and Termination of Its Shipping and Consulting Agreement with WellDyne Health
ACCESSWIRE - Thu Jun 11, 8:00AM CDT
ADDISON, TX / ACCESSWIRE / June 11, 2015 / Wound Management Technologies, Inc. (OTCQB:WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced amending and terminating of its Shipping and Consulting Agreement dated September 19, 2013 with WellDyne Health in order to focus on its strategic shift to focus on sales internally.
Wound Management Technologies Reports Record Preliminary Financial Results for the First Quarter of 2015 and Enhanced Sales Team
ACCESSWIRE - Wed Apr 22, 9:12AM CDT
ADDISON, TX / ACCESSWIRE / April 22, 2015 / Wound Management Technologies, Inc. (OTCQB:WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced record preliminary financial and operating results for the first quarter of 2015 and additions to its sales management team.
Wound Management Technologies, Inc. Schedules First Quarter 2015 Earnings Call for Wednesday, April 22, 2015
ACCESSWIRE - Mon Apr 20, 3:30PM CDT
ADDISON, TX / ACCESSWIRE / April 20, 2015 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced it will conduct a quarterly earnings call on Wednesday, April 22, 2015 at 3:00 p.m. CST. Robert Lutz, Jr., CEO, will discuss first quarter 2015 results and provide and update on recent activities. A question and answer session will follow the presentation. Shareholders, analysts and other interested parties may join the call by dialing 1-712-775-7031 passcode 604070847# shortly before 3:00 p.m. CST.
Wound Management Technologies Reports Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014
ACCESSWIRE - Thu Apr 09, 8:00AM CDT
ADDISON, TX / ACCESSWIRE / April 9, 2015 / Wound Management Technologies, Inc. (OTCQB:WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced its financial and operating results for the fourth quarter and full year ended December 31, 2014.
Wound Management Technologies Exhibits at the American Academy of Orthopaedic Surgeons 2015 Annual Meeting
ACCESSWIRE - Wed Mar 18, 7:30AM CDT
ADDISON, TX / ACCESSWIRE / March 18, 2015 / Wound Management Technologies, Inc. (OTCQB:WNDM) ("Company"
, an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that its subsidiary, Wound Care Innovations ("WCI" , will be an exhibitor at the American Academy of Orthopaedic Surgeons ("AAOS" Annual Meeting on March 24-28, to be held at the Venetian/Sands Expo in Las Vegas, Nevada. Wound Care Innovations will be located at booth #6729.
Wound Management Technologies Expands Internationally with Inaugural Order from Mexico
ACCESSWIRE - Mon Mar 16, 7:30AM CDT
ADDISON, TX / ACCESSWIRE / March 16, 2015 / Wound Management Technologies, Inc. (OTCQB:WNDM) ("Company" , an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that Wound Care Innovations ("WCI" , a subsidiary of the Company, received its inaugural order from Mexico, where WCI is registered and signed a distribution agreement with VISECA Desarrollo Inmobiliario SA de CA ("VISECA" , a healthcare distributor in Mexico. CellerateRX(R) received COFEPRIS approval from the Mexico Ministry of Health.
Wound Management Technologies Reports Preliminary Financial Results For the Fourth Quarter and Year Ended December 31, 2014
ACCESSWIRE - Thu Jan 29, 7:31AM CST
ADDISON, TX / ACCESSWIRE / January 29, 2015 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced preliminary financial and operating results for the fourth quarter and year ended December 31, 2014.
Wound Management Technologies Appoints John Siedhoff to its Board of Directors
ACCESSWIRE - Tue Jan 13, 7:31AM CST
ADDISON, TX / ACCESSWIRE / January 13, 2015 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), announces that the Company has appointed John Siedhoff to its Board of Directors.
Wound Management Technologies Reports Financial Results for the Third Quarter Ended September 30, 2014
ACCESSWIRE - Thu Nov 13, 7:35AM CST
Addison, TX / ACCESSWIRE / November 13, 2014 / Wound Management Technologies, Inc. (OTC QB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced its financial and operating results for the three month period ended September 30, 2014.
Wound Management Technologies Appoints Ronald Goode and Jeffrey Lewis to the Board of Directors
Marketwired - Tue Oct 21, 7:30AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), announces that the Company appointed Ronald Goode and Jeffrey Lewis to the Board of Directors.
Wound Management Technologies' CellerateRX(R) Featured in Clinical Research Session at the Symposium of Advanced Wound Care (SAWC) in Las Vegas, NV
Marketwired - Thu Oct 16, 7:30AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that the product will be featured in an abstract accepted to the clinical research session at the Symposium of Advanced Wound Care (SAWC), which is being held at the Caesars Palace in Las Vegas, NV on October 16th - 18th, 2014.
Q2 2016 Sales Up 69% over Q2 2015, and 2016 YTD Sales Up 34% over 2015 YTD Sales for Wound Management Technologies
ACCESSWIRE - Fri Aug 12, 8:30AM CDT
ADDISON, TX / ACCESSWIRE / August 12, 2016 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX®, today announced its continued sales growth.
Wound Management Technologies Reports Positive Net Income for Q1 Ended March 31, 2016
ACCESSWIRE - Mon May 16, 8:30AM CDT
ADDISON, TX / ACCESSWIRE / May 16, 2016 / Wound Management Technologies, Inc. (OTC QB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX®, today announced that its sales growth and cost reducing measures have resulted in positive net income for the quarter This achieves a major corporate strategic milestone.
Wound Management Technologies Reports Record Preliminary Financial Results For Q1 Ended March 31, 2016
ACCESSWIRE - Tue Apr 19, 7:31AM CDT
ADDISON, TX / ACCESSWIRE / April 19, 2016 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX®, today announced record preliminary financial and operating results for Q1 ended March 31, 2016.
Wound Management Technologies Reports Preliminary Financial Results For Year Ended December 31, 2015
ACCESSWIRE - Thu Apr 07, 7:30AM CDT
ADDISON, TX / ACCESSWIRE / April 7, 2016 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX®, today announced preliminary financial and operating results for year ended December 31, 2015.
Markets for Advanced Wound Management Technologies
M2 - Mon Jan 04, 3:08AM CST
REPORT HIGHLIGHTS
Global Medical Devices: Quarterly Investments Review Featuring the Most Recent 200 Business Transactions
M2 - Tue Oct 20, 6:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mqnnl4/global_medical) has announced the addition of the "Global Medical Devices: Quarterly Investments Review " report to their offering. The 'Global Medical Devices: Quarterly Investments Review report' presents the most recent 200 business transactions between the global medical devices/technology/supplies companies are identified, segregated and analyzed to highlight the scope of investments in different sub-industry sectors. Medical device companies are expected to realign their business structures and strategies to compete in the changing global environment (such as growth of emerging markets, health care reform and cost containment). Anticipated changes include company restructuring as well as an increased reliance on strategic alliances and outsourcing for marketing, distribution, research and manufacturing activities. In this context, the author which has been providing company and financial information globally since two decades, brings out Global Medical Devices: Quarterly Investments Review report for global medical devices/technology/supplies companies. Report Highlights: - A guidance business tool which helps the investors in the global medical devices/technology/supplies industry to assess the investment opportunities for the coming months - Helps the investors to familiarize with the existing investment trends in the global medical devices/technology/supplies industry - Helps the global medical devices/technology/supplies companies to know the prevailing sub-industry trends in the global medical devices/technology/supplies business transactions - Presents the key investment strategies applied by the global medical devices/technology/supplies companies - Highlights the favored countries for the deals by the global medical devices/technology/supplies companies - Useful information on trade facilitators' activities to accelerate global medical devices/technology/supplies commerce - Summarizes the recent regulatory developments that are likely to affect the trade approaches of the global medical devices/technology/supplies industry - Summarizes new policies of various governments in global medical devices/technology/supplies industry and its impact on investments globally - Provides at one glance the listing of important transactions across the global medical devices/ technology/supplies sector Companies Mentioned - Simavita Ltd (Australia) - Solborn Incorporated (South Korea) - Sorin SpA (Italy) - Strand Life Sciences Private Limited (India) - Stratec Biomedical AG (Germany) - Straumann Holding AG (Switzerland) - Sunshine Holdings PLC (Sri Lanka) - Sysmex Corporation (Japan) - Thermo Fisher Scientific Inc (United States) - Tornier NV (Netherlands) - Toumaz Limited (United Kingdom) - TSO3 Inc (Canada) - Varian Medical Systems, Inc. (United States) - Vivoline Medical AB (Sweden) - Voxel SA (Poland) - William Demant Holding (Denmark) - Wound Management Technologies, Inc. (United States) - Yamato Scientific Co, Ltd (Japan) - Zecotek Photonics Inc (Canada) - Zhejiang DA Diagnostics Co Ltd (China) For more information visit http://www.researchandmarkets.com/research/mq...al_medical
VAR: 94.92 (-0.22), TRNX: 20.67 (+0.28)
Wound Management Technologies Reports Preliminary Financial Results for the Third Quarter of 2015
ACCESSWIRE - Wed Oct 07, 3:10PM CDT
ADDISON, TX / ACCESSWIRE / October 7, 2015 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced preliminary financial and operating results for the third quarter and nine months ended September 30, 2015.
Wound Management Technologies Elects Mr. James W. Stuckert to the Board of Directors
ACCESSWIRE - Thu Sep 24, 2:58PM CDT
ADDISON, TX / ACCESSWIRE / September 24, 2015 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that Mr. James W. Stuckert was elected to the Board of Directors of the Company at its September 21, 2015 board meeting.
Wound Management Technologies Receives Investment; Fully Pays Notes to Brookhaven Medical, Inc.; Mr. S. Oden Howell, Jr. Appointed to the Board of Directors
ACCESSWIRE - Thu Jun 18, 7:30AM CDT
ADDISON, TX / ACCESSWIRE / June 18, 2015 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that it has fully paid short term loans due to Brookhaven Medical Inc. This was made possible by investments from existing shareholders.
Wound Management Technologies Reports Amending and Termination of Its Shipping and Consulting Agreement with WellDyne Health
ACCESSWIRE - Thu Jun 11, 8:00AM CDT
ADDISON, TX / ACCESSWIRE / June 11, 2015 / Wound Management Technologies, Inc. (OTCQB:WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced amending and terminating of its Shipping and Consulting Agreement dated September 19, 2013 with WellDyne Health in order to focus on its strategic shift to focus on sales internally.
Wound Management Technologies Reports Record Preliminary Financial Results for the First Quarter of 2015 and Enhanced Sales Team
ACCESSWIRE - Wed Apr 22, 9:12AM CDT
ADDISON, TX / ACCESSWIRE / April 22, 2015 / Wound Management Technologies, Inc. (OTCQB:WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced record preliminary financial and operating results for the first quarter of 2015 and additions to its sales management team.
Wound Management Technologies, Inc. Schedules First Quarter 2015 Earnings Call for Wednesday, April 22, 2015
ACCESSWIRE - Mon Apr 20, 3:30PM CDT
ADDISON, TX / ACCESSWIRE / April 20, 2015 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced it will conduct a quarterly earnings call on Wednesday, April 22, 2015 at 3:00 p.m. CST. Robert Lutz, Jr., CEO, will discuss first quarter 2015 results and provide and update on recent activities. A question and answer session will follow the presentation. Shareholders, analysts and other interested parties may join the call by dialing 1-712-775-7031 passcode 604070847# shortly before 3:00 p.m. CST.
Wound Management Technologies Reports Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014
ACCESSWIRE - Thu Apr 09, 8:00AM CDT
ADDISON, TX / ACCESSWIRE / April 9, 2015 / Wound Management Technologies, Inc. (OTCQB:WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced its financial and operating results for the fourth quarter and full year ended December 31, 2014.
Wound Management Technologies Exhibits at the American Academy of Orthopaedic Surgeons 2015 Annual Meeting
ACCESSWIRE - Wed Mar 18, 7:30AM CDT
ADDISON, TX / ACCESSWIRE / March 18, 2015 / Wound Management Technologies, Inc. (OTCQB:WNDM) ("Company"
, an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that its subsidiary, Wound Care Innovations ("WCI" , will be an exhibitor at the American Academy of Orthopaedic Surgeons ("AAOS" Annual Meeting on March 24-28, to be held at the Venetian/Sands Expo in Las Vegas, Nevada. Wound Care Innovations will be located at booth #6729. Wound Management Technologies Expands Internationally with Inaugural Order from Mexico
ACCESSWIRE - Mon Mar 16, 7:30AM CDT
ADDISON, TX / ACCESSWIRE / March 16, 2015 / Wound Management Technologies, Inc. (OTCQB:WNDM) ("Company"
, an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that Wound Care Innovations ("WCI" , a subsidiary of the Company, received its inaugural order from Mexico, where WCI is registered and signed a distribution agreement with VISECA Desarrollo Inmobiliario SA de CA ("VISECA" , a healthcare distributor in Mexico. CellerateRX(R) received COFEPRIS approval from the Mexico Ministry of Health. Wound Management Technologies Reports Preliminary Financial Results For the Fourth Quarter and Year Ended December 31, 2014
ACCESSWIRE - Thu Jan 29, 7:31AM CST
ADDISON, TX / ACCESSWIRE / January 29, 2015 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced preliminary financial and operating results for the fourth quarter and year ended December 31, 2014.
Wound Management Technologies Appoints John Siedhoff to its Board of Directors
ACCESSWIRE - Tue Jan 13, 7:31AM CST
ADDISON, TX / ACCESSWIRE / January 13, 2015 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), announces that the Company has appointed John Siedhoff to its Board of Directors.
Wound Management Technologies Reports Financial Results for the Third Quarter Ended September 30, 2014
ACCESSWIRE - Thu Nov 13, 7:35AM CST
Addison, TX / ACCESSWIRE / November 13, 2014 / Wound Management Technologies, Inc. (OTC QB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced its financial and operating results for the three month period ended September 30, 2014.
Wound Management Technologies Appoints Ronald Goode and Jeffrey Lewis to the Board of Directors
Marketwired - Tue Oct 21, 7:30AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), announces that the Company appointed Ronald Goode and Jeffrey Lewis to the Board of Directors.
Wound Management Technologies' CellerateRX(R) Featured in Clinical Research Session at the Symposium of Advanced Wound Care (SAWC) in Las Vegas, NV
Marketwired - Thu Oct 16, 7:30AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that the product will be featured in an abstract accepted to the clinical research session at the Symposium of Advanced Wound Care (SAWC), which is being held at the Caesars Palace in Las Vegas, NV on October 16th - 18th, 2014.
